US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

AI Healthcare

611.92

-13.4269-2.15%

Number of Gainers:1

Number of Losers:3

Number of Flat:- -

PE:- -

High:625.56

Open:625.56

Low:604.19

Close:625.35

Volume:15.61M

Turnover:267.53M

Market Cap:19.03B

Float Cap:14.56B

Loading ...

Tempus AI CEO Data Ryan Fukushima Disposes of 20.000 Shares Worth $1 Juta

Tempus AI (TEM) After CellCarta Deal And PRISM2 Validation Faces A Fresh Valuation Test

Simply Wall St.

Why Tempus AI (TEM) Is Up 18.6% After Joining CellCarta’s CDx Commercialization Lab Network

Simply Wall St.

Analysts Offer Insights on Healthcare Companies: Beam Therapeutics (BEAM), OmniAb (OABI) and Astrana Health (ASTH)

Recursion Director Blake Borgeson Disposes of 30,000 Shares for $97,500

Oculis Q2 Net Loss Narrows Despite Higher Expenses

Cellcarta: Adds Tempus to Cdx Commercialization Lab Network as Second Commercial Lab Partner

THOMSON REUTERS

Intellia Therapeutics Q2 Collaboration Revenue Falls, Net Loss Widens

Primer: Recursion Pharmaceuticals (RXRX US) - Aug 2026

Tempus AI CEO, Data Ryan Fukushima Reports Disposal of 23,818 Common Shares Worth $1.1 Million

Editas Medicine Q2 Net Loss Narrows and Beats Estimates

Analysts’ Opinions Are Mixed on These Healthcare Stocks: Geron (GERN), Zimmer Biomet Holdings (ZBH) and Recursion Pharmaceuticals (RXRX)

Recursion Pharmaceuticals, Inc. Reports Results for the Quarter Ended June 30 - Earnings Summary

Analysts Offer Insights on Healthcare Companies: Waters (WAT), Beam Therapeutics (BEAM) and Green Thumb Industries (OtherGTBIF)

Crispr Therapeutics AG (CRSP) Receives a Hold from Wells Fargo

Recursion Q2 2026 earnings: Expense cuts narrow the net loss

Earnings Flash (RXRX) Recursion Pharmaceuticals Posts Q2 Loss $0.25 a Share, vs. FactSet Est of $0.28 Loss

MT Newswires Live

Recursion Pharmaceuticals Q2 Operating Revenue USD 7.303 Million Vs. IBES Estimate USD 11.9 Million

Recursion Pharmaceuticals Q2 Revenue Misses Estimates, Cuts 2026 Expense Outlook

Recursion Pharmaceuticals Shares Fall 9% Premarket After Q2 Revenue Miss

THOMSON REUTERS

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/BK4611/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BK4611","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK4611\",,,,,undefined,":{"symbol":"BK4611","market":"US","secType":"PLATE","nameCN":"AI Healthcare","latestPrice":611.922,"timestamp":1786737599999,"preClose":625.3489,"halted":0,"volume":15605073,"delay":0,"changeRate":-0.021471,"floatShares":0,"shares":0,"eps":0,"marketStatus":"Market Closed","change":-13.42688,"latestTime":"08-14 16:00:00 EDT","open":625.56323,"high":625.56323,"low":604.1918,"amount":267531092.097252,"amplitude":0.034175,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1786953600000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"pbRate":4.657559,"peRate":-14.828987,"turnoverRate":0.019463,"increases":1,"decrements":3,"flats":0,"marketCap":19032084608,"floatMarketCap":14555207936},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK4611\",,,,,undefined,":{"symbol":"BK4611","high":625.56323,"amplitude":0.034175,"preClose":625.3489,"low":604.1918,"pbRate":"4.657559","latestPrice":611.922,"volume":15605073,"delay":0,"open":625.56323,"prevYearClose":658.3995,"prevWeekClose":614.7909,"prevMonthClose":543.3925,"prevQuarterClose":681.0329,"fiveDayClose":614.7909,"twentyDayClose":590.2628,"sixtyDayClose":550.7017,"secType":"PLATE","market":"US","turnoverRate":0.019463,"peRate":-14.828987,"marketCap":19032084608,"floatMarketCap":14555207936,"timestamp":1786737599999,"nameCN":"AI Healthcare"},"@#url:\"https://hq.skytigris.cn/api/global/plate/up_down\",method:\"POST\",data:#delay:false,bkCodes:@\"BK4611\",,,,undefined,":{"bkCode":"BK4611","up":1,"down":3,"flat":0},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK4611\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2658946487","title":"Tempus AI CEO Data Ryan Fukushima Disposes of 20.000 Shares Worth $1 Juta","url":"https://stock-news.laohu8.com/highlight/detail?id=2658946487","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658946487?lang=en_us&edition=fundamental","pubTime":"2026-08-12 05:30","pubTimestamp":1786483817,"startTime":"0","endTime":"0","summary":"Tempus AI CEO Data Ryan Fukushima disposes of 20.000 shares worth $1 jutaTempus AI Inc.: Ryan Fukushima, CEO, Data, melaporkan penjualan 20.000 saham Class A pada 7 Agustus 2026.Saham dijual pada harg","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260811:nNDL65Rs5B:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"Tempus AI CEO Data Ryan Fukushima Disposes of 20.000 Shares Worth $1 Juta","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4121","ARKG","TEMT","BK4611","LU1861559042.SGD","HEAL","BK4613","LU1861558580.USD","TEM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658670176","title":"Tempus AI (TEM) After CellCarta Deal And PRISM2 Validation Faces A Fresh Valuation Test","url":"https://stock-news.laohu8.com/highlight/detail?id=2658670176","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658670176?lang=en_us&edition=fundamental","pubTime":"2026-08-10 00:30","pubTimestamp":1786293017,"startTime":"0","endTime":"0","summary":"Tempus AI (TEM) is back in focus after CellCarta added the company to its CDx Commercialization Lab Network, linking Tempus Hub ordering to CellCarta testing and tightening access to oncology companion diagnostics for U.S. providers.\nSee our latest analysis for Tempus AI.\nTempus AI’s recent CellCarta partnership, PRISM2 publication and earnings update have arrived alongside a sharp 1-day share price return of 12.86% and a 7-day share price return of 18.65%. However, the year-to-date share...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/9551728-choice1-main-header/1585186657000","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/9551728-choice1-main-header/1585186657000"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-tem/tempus-ai/news/tempus-ai-tem-after-cellcarta-deal-and-prism2-validation-fac","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-tem/tempus-ai/news/tempus-ai-tem-after-cellcarta-deal-and-prism2-validation-fac","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["HEAL","LU1861559042.SGD","ARKG","BK4613","BK4121","TEMT","LU1861558580.USD","BK4611","TEM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657845678","title":"Why Tempus AI (TEM) Is Up 18.6% After Joining CellCarta’s CDx Commercialization Lab Network","url":"https://stock-news.laohu8.com/highlight/detail?id=2657845678","media":"Simply Wall St.","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657845678?lang=en_us&edition=fundamental","pubTime":"2026-08-08 20:31","pubTimestamp":1786192260,"startTime":"0","endTime":"0","summary":"On 6 August 2026, CellCarta Inc. said it would add Tempus AI to its CDx Commercialization Lab Network, with Tempus using its Tempus Hub to manage provider test ordering, sample routing to CellCarta, and result delivery for oncology-focused companion diagnostics in the U.S.\nThis collaboration links Tempus AI’s ordering and data platform with CellCarta’s development and regulatory capabilities, aiming to close the gap between CDx approval and real-world clinical access for cancer...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/9551728-choice1-main-header/1585186657000","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/9551728-choice1-main-header/1585186657000"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-tem/tempus-ai/news/why-tempus-ai-tem-is-up-186-after-joining-cellcartas-cdx-com","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-tem/tempus-ai/news/why-tempus-ai-tem-is-up-186-after-joining-cellcartas-cdx-com","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4611","TEMT","LU1861559042.SGD","LU1861558580.USD","TEM","ARKG","HEAL","BK4613","BK4121"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657433647","title":"Analysts Offer Insights on Healthcare Companies: Beam Therapeutics (BEAM), OmniAb (OABI) and Astrana Health (ASTH)","url":"https://stock-news.laohu8.com/highlight/detail?id=2657433647","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657433647?lang=en_us&edition=fundamental","pubTime":"2026-08-07 23:50","pubTimestamp":1786117814,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Beam Therapeutics (BEAM), OmniAb (OABI) and Astrana ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-beam-therapeutics-beam-omniab-oabi-and-astrana-health-asth-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-beam-therapeutics-beam-omniab-oabi-and-astrana-health-asth-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BEAM","BK4611","BK4535","ASTH","HCSG","BK4581","BK4139","LABU","XLV","BK4588","LU0029874061.USD","BK4196","BK4137","LU1861558580.USD","BK4585","OABI","XBI","LU1861559042.SGD","BK4121","LU0128526141.USD","BK4505","BK4556"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657665036","title":"Recursion Director Blake Borgeson Disposes of 30,000 Shares for $97,500","url":"https://stock-news.laohu8.com/highlight/detail?id=2657665036","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657665036?lang=en_us&edition=fundamental","pubTime":"2026-08-07 05:24","pubTimestamp":1786051497,"startTime":"0","endTime":"0","summary":"Recursion director Blake Borgeson disposes of 30,000 shares for $97,500Recursion Pharmaceuticals director Blake Borgeson sold 30,000 Class A common shares on Aug. 4 at $3.25.Direct holdings fell to 6,","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260806:nNDL9pSDDB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Recursion Director Blake Borgeson Disposes of 30,000 Shares for $97,500","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4548","BK4139","BK4611","RXRX","BK4609","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657668929","title":"Oculis Q2 Net Loss Narrows Despite Higher Expenses","url":"https://stock-news.laohu8.com/highlight/detail?id=2657668929","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657668929?lang=en_us&edition=fundamental","pubTime":"2026-08-07 04:32","pubTimestamp":1786048350,"startTime":"0","endTime":"0","summary":"Oculis Q2 net loss narrows despite higher expensesOverviewBiopharma firm's Q2 net loss narrowed yr/yr as operating expenses roseOperating expenses increased, mainly from higher headcount and share-bas","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260806:nL1N4431F0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ARKG","CRSP","BK4556","LU1861559042.SGD","BK4007","ALGS","LU1861558580.USD","BK4611","BK4505","BK4585","BK4139","BK4588","OCS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657063288","title":"Cellcarta: Adds Tempus to Cdx Commercialization Lab Network as Second Commercial Lab Partner","url":"https://stock-news.laohu8.com/highlight/detail?id=2657063288","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657063288?lang=en_us&edition=fundamental","pubTime":"2026-08-06 21:15","pubTimestamp":1786022156,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260806:nFWN4430X9:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU1861559042.SGD","BK4121","BK4613","TEMT","ARKG","TEM","HEAL","BK4611","LU1861558580.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657560633","title":"Intellia Therapeutics Q2 Collaboration Revenue Falls, Net Loss Widens","url":"https://stock-news.laohu8.com/highlight/detail?id=2657560633","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657560633?lang=en_us&edition=fundamental","pubTime":"2026-08-06 19:20","pubTimestamp":1786015252,"startTime":"0","endTime":"0","summary":"Intellia Therapeutics Q2 collaboration revenue falls, net loss widensOverviewU.S. gene editing firm's Q2 collaboration revenue fell yr/yr due to lower Regeneron revenueQ2 net loss widened from prior y","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260806:nL1N4430JC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NTLA","IBBQ","LU2468319806.SGD","LU1861558580.USD","BBH","LU2106854487.HKD","LU0053666078.USD","LU0109394709.USD","LU2362541513.USD","LU2023250504.SGD","BK4535","LU2362540622.SGD","TBXU","LU2237438978.USD","LU0882574055.USD","LU2089984988.USD","LU1861559042.SGD","REGN","BK4139","LU0823416689.USD","LU0114720955.EUR","LU2362541273.HKD","ARKG","BK4556","LU1974910355.USD","LU0320765992.SGD","LU0823434583.USD","LU0058720904.USD","IBB","LU0889565916.HKD","BK4588","LU0823434740.USD","BK4585","BK4611","LU1917777945.USD","CRSP","EDIT","LU0289739699.SGD","PGEN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657656215","title":"Primer: Recursion Pharmaceuticals  (RXRX US) - Aug 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2657656215","media":"Smartkarma","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657656215?lang=en_us&edition=fundamental","pubTime":"2026-08-06 16:29","pubTimestamp":1786004987,"startTime":"0","endTime":"0","summary":"utm_source=tiger_community","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.smartkarma.com/home/private-investor-solutions/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4539","BK4548","BK4611","RXRX","BK4609","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657573633","title":"Tempus AI CEO, Data Ryan Fukushima Reports Disposal of 23,818 Common Shares Worth $1.1 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2657573633","media":"Reuters","labels":["insiderTrades","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657573633?lang=en_us&edition=fundamental","pubTime":"2026-08-06 04:31","pubTimestamp":1785961911,"startTime":"0","endTime":"0","summary":"Tempus AI CEO, Data Ryan Fukushima reports disposal of 23,818 common shares worth $1.1 millionTempus AI officer Ryan Fukushima, CEO, Data, reported sales of Class A common stock held indirectly by his","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260805:nNDL72gwyv:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"Tempus AI CEO, Data Ryan Fukushima Reports Disposal of 23,818 Common Shares Worth $1.1 Million","news_tag":"insiderTrades,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HEAL","LU1861558580.USD","BK4121","ARKG","LU1861559042.SGD","TEM","TEMT","BK4613","BK4611"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657752095","title":"Editas Medicine Q2 Net Loss Narrows and Beats Estimates","url":"https://stock-news.laohu8.com/highlight/detail?id=2657752095","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657752095?lang=en_us&edition=fundamental","pubTime":"2026-08-06 04:11","pubTimestamp":1785960676,"startTime":"0","endTime":"0","summary":"Editas Medicine Q2 net loss narrows and beats estimatesOverviewUS gene editing firm's Q2 net loss narrowed and beat analyst expectationsCollaboration and other R&D revenue more than tripled yr/yr to $","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260805:nL1N4421AG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CRSP","TRDA","BK4588","KYMR","BK4585","BK4556","BK4139","BK4611","ARKG","EDIT","LU1861559042.SGD","LU1861558580.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657522957","title":"Analysts’ Opinions Are Mixed on These Healthcare Stocks: Geron (GERN), Zimmer Biomet Holdings (ZBH) and Recursion Pharmaceuticals (RXRX)","url":"https://stock-news.laohu8.com/highlight/detail?id=2657522957","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657522957?lang=en_us&edition=fundamental","pubTime":"2026-08-06 03:10","pubTimestamp":1785957008,"startTime":"0","endTime":"0","summary":"Analysts have been eager to weigh in on the Healthcare sector with new ratings on Geron (GERN), Zimmer Biomet Holdings (ZBH) and Recursion Pharmace...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-opinions-are-mixed-on-these-healthcare-stocks-geron-gern-zimmer-biomet-holdings-zbh-and-recursion-pharmaceuticals-rxrx-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-opinions-are-mixed-on-these-healthcare-stocks-geron-gern-zimmer-biomet-holdings-zbh-and-recursion-pharmaceuticals-rxrx-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4566","BK4548","LU0792757196.USD","LU0128525929.USD","GERN","LU1201861249.SGD","IE00B19Z3581.USD","BK4609","LU0130102774.USD","BK4504","IE00B19Z3B42.SGD","BK4082","LU0648001328.SGD","LU1267930573.SGD","LU1267930813.SGD","LU0477156953.USD","BK4539","IE0002270589.USD","BK4139","LU0211327993.USD","ZBH","RXRX","LU0006061336.USD","LU0211328371.USD","LU0889566641.SGD","LU0310799852.SGD","LU0310800379.SGD","LU0130517989.USD","BK4588","IE00B7SZLL34.SGD","BK4585","BK4611","LU0708994859.HKD","LU0029864427.USD","LU0980610538.SGD","LU1267930490.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657390540","title":"Recursion Pharmaceuticals, Inc. Reports Results for the Quarter Ended June 30 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2657390540","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657390540?lang=en_us&edition=fundamental","pubTime":"2026-08-05 21:30","pubTimestamp":1785936652,"startTime":"0","endTime":"0","summary":"Recursion Pharmaceuticals, Inc. reports results for the quarter ended June 30 - Earnings SummaryRecursion Pharmaceuticals, Inc.RXRX.OQreported a quarterly adjusted loss of 25 cents per share for the q","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260805:nL8N44222C:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4609","BK4539","BK4548","BK4139","BK4611","RXRX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657257544","title":"Analysts Offer Insights on Healthcare Companies: Waters (WAT), Beam Therapeutics (BEAM) and Green Thumb Industries (OtherGTBIF)","url":"https://stock-news.laohu8.com/highlight/detail?id=2657257544","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657257544?lang=en_us&edition=fundamental","pubTime":"2026-08-05 20:10","pubTimestamp":1785931809,"startTime":"0","endTime":"0","summary":"Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Waters (WAT), Beam Therapeutics (BEAM) and Green T...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-waters-wat-beam-therapeutics-beam-and-green-thumb-industries-othergtbif-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-waters-wat-beam-therapeutics-beam-and-green-thumb-industries-othergtbif-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4535","LU0029874061.USD","LABU","BK4611","WAT","LU0690374615.EUR","BK4505","LU2404859741.USD","BK4588","BK4137","LU0128526141.USD","BK4556","XLV","LU1861558580.USD","GB00B4QBRK32.GBP","GB00B4LPDJ14.GBP","HCSG","LU2413666426.HKD","LU1861559042.SGD","LU2413666699.HKD","BK4581","LU0690374961.EUR","BK4585","LU1721428933.USD","BK4121","BEAM","LU2404859667.USD","LU0347712357.USD","XBI","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657541254","title":"Crispr Therapeutics AG (CRSP) Receives a Hold from Wells Fargo","url":"https://stock-news.laohu8.com/highlight/detail?id=2657541254","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657541254?lang=en_us&edition=fundamental","pubTime":"2026-08-05 19:49","pubTimestamp":1785930575,"startTime":"0","endTime":"0","summary":"Wells Fargo analyst Yanan Zhu maintained a Hold rating on Crispr Therapeutics AG today and set a price target of $75.00. Zhu covers the Healthcare ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/crispr-therapeutics-ag-crsp-receives-a-hold-from-wells-fargo-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/crispr-therapeutics-ag-crsp-receives-a-hold-from-wells-fargo-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU1074936037.SGD","FTXO","IYF","LU2361044865.SGD","ARKG","LU1894683348.USD","SLJY","LU2461242641.AUD","LU0289960550.SGD","IE000M9KFDE8.USD","SLVX","BK4588","LU0320765489.SGD","KBWB","LABU","XBI","LU0251142724.SGD","LU0314106906.USD","LU0310800965.SGD","LU1791807156.HKD","SILJ","LU0211327993.USD","SLVR","LU0130517989.USD","LU0310800379.SGD","BK4139","CRSP","BK4501","LU1035773651.USD","TFNS","BK4582","BK4559","LU0742534661.SGD","LU1814569148.SGD","PGF","LU0106831901.USD","LU0477156953.USD","LU0052756011.USD","BK4611","LU0162691827.USD","LU0648001328.SGD","LU2236285917.USD","IE00B19Z3B42.SGD","LU0128525689.USD","BK4585","XLV","LU1506573853.SGD","BK4504","AG","LU0029864427.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657413541","title":"Recursion Q2 2026 earnings: Expense cuts narrow the net loss","url":"https://stock-news.laohu8.com/highlight/detail?id=2657413541","media":"TradingKey","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657413541?lang=en_us&edition=fundamental","pubTime":"2026-08-05 18:58","pubTimestamp":1785927511,"startTime":"0","endTime":"0","summary":"Recursion’s Q2 2026 revenue fell to $7.7 million from $19.2 million as Roche and Genentech revenue declined following completion of certain project phases. GAAP diluted loss per share improved to $0.25 from $0.41, and net loss narrowed to $131.0 million from $171.9 million as R&D and G&A expenses decreased. Quarterly operating cash use rose to $105.9 million, while cash, cash equivalents and restricted cash ended June at $556.8 million. Recursion lowered its 2026 cash operating expense ceiling to below $375 million and maintained cash runway guidance into early 2028.","market":"nz","thumbnail":"https://resource.tradingkey.com/cdn/images/article/news/stock6.jpg","type":0,"news_type":0,"thumbnails":["https://resource.tradingkey.com/cdn/images/article/news/stock6.jpg"],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tradingkey.com/news/earnings/262077414-tradingkey","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4609","BK4539","BK4548","RXRX","BK4611","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657543089","title":"Earnings Flash (RXRX) Recursion Pharmaceuticals Posts Q2 Loss $0.25 a Share, vs. FactSet Est of $0.28 Loss","url":"https://stock-news.laohu8.com/highlight/detail?id=2657543089","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657543089?lang=en_us&edition=fundamental","pubTime":"2026-08-05 18:45","pubTimestamp":1785926758,"startTime":"0","endTime":"0","summary":"Earnings Flash (RXRX) Recursion Pharmaceuticals Posts Q2 Loss $0.25 a Share, vs. FactSet Est of $0.28 Loss","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4611","BK4539","BK4609","RXRX","BK4139","BK4548"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657432965","title":"Recursion Pharmaceuticals Q2 Operating Revenue USD 7.303 Million Vs. IBES Estimate USD 11.9 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2657432965","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657432965?lang=en_us&edition=fundamental","pubTime":"2026-08-05 18:43","pubTimestamp":1785926593,"startTime":"0","endTime":"0","summary":"Aug 05 (Reuters) - Recursion Pharmaceuticals Q2 pretax profit USD -131.006 million.:((Reuters Investor Briefs; email: reutersinvestor.briefs@thomsonreuters.com))Source Date/Time = 05-AUG-202610:29:08.17 GMT","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260805:nRSD9jmn2G:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4611","BK4609","BK4548","BK4539","RXRX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657954328","title":"Recursion Pharmaceuticals Q2 Revenue Misses Estimates, Cuts 2026 Expense Outlook","url":"https://stock-news.laohu8.com/highlight/detail?id=2657954328","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657954328?lang=en_us&edition=fundamental","pubTime":"2026-08-05 18:42","pubTimestamp":1785926539,"startTime":"0","endTime":"0","summary":"Recursion Pharmaceuticals Q2 revenue misses estimates, cuts 2026 expense outlookOverviewUS drug discovery firm's Q2 operating revenue fell and missed analyst expectationsQ2 net loss narrowed yr/yr but","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260805:nL1N4420FP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4611","BK4139","RXRX","BK4609","BK4539","BK4548"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657543986","title":"Recursion Pharmaceuticals Shares Fall 9% Premarket After Q2 Revenue Miss","url":"https://stock-news.laohu8.com/highlight/detail?id=2657543986","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657543986?lang=en_us&edition=fundamental","pubTime":"2026-08-05 18:37","pubTimestamp":1785926270,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260805:nL4N44210D:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["RXRX","BK4548","BK4139","BK4539","BK4611","BK4609"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":3,"pageCount":1,"totalSize":60,"code":"91000000","status":"200"}]}}